NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Model Medicines Partners with Sanford Burnham Prebys on AI-driven Drug Discovery
Model Medicines, an AI drug discovery software company, has entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
The collaboration leverages Model Medicines’ ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, in conjunction with Sanford Burnham Prebys’ identification of novel antiviral targets and deep scientific expertise, to discover and develop new treatments for SARS-CoV-2 and other infectious diseases.
The partnership will initially focus on COVID-19 with a long-term vision of both Sanford Burnham Prebys and Model Medicines to develop and advance broad-spectrum antivirals for the infectious diseases of today and those yet unknown in the future. While pandemics like COVID-19 are not expected on a yearly basis, it is widely understood that the international community will encounter these pandemics at a significantly higher frequency. There is an immediate and ongoing need to develop broad-spectrum antivirals that are ready to be dosed globally at a moment’s notice to meet these challenges. The application of novel, validated therapeutics at the onset of an outbreak has the potential to significantly reduce the loss of life and the disruption to the global economy wrought by future infectious diseases.
Model Medicines has created an infectious disease specific version of their ActivPred AI Drug Discovery Platform that focuses exclusively on identifying safe and effective, non-obvious therapeutics with activity against the novel biological targets identified by Sanford Burnham Prebys. Their digital chemistry drug discovery platform leverages artificial intelligence based on fundamental chemistry to discover drugs active against these novel biological targets that cannot be resolved with traditional high throughput screening approaches.
nference Study Reveals Pre-Existing Conditions to Be a Significant Factor in COVID Patients Who Are Hospitalized Post-Viral Clearance
AI technology implemented by nference on vast amounts of biomedical data during the COVID-19 pandemic has enabled discoveries with a wide range of implications that contribute to a greater understanding of the virus and, ultimately, are advancing patient care.
A study involving nference, “Pre-existing conditions are associated with COVID patients hospitalization, despite confirmed clearance of SARS-CoV-2 virus,” recently published in EClinicalMedicine sheds light on the phenomenon of patients infected with SARS-CoV-2 who have been tested as cleared of the virus yet required hospitalizations.
The study, conducted by nference data scientists and physicians from Mayo Clinic, indicates that COVID-19 patients hospitalized post-viral clearance had higher rates of pre-COVID acute kidney injury, anemia, and cardiac arrhythmias as underlying conditions. The report also finds that pre-COVID conditions generally associated with poorer outcomes during a SARS-CoV-2 infection — hypertension, asthma, obstructive sleep apnea, obesity, and diabetes — were not significantly increased among patients hospitalized after clearance.
The nference study conducted a retrospective analysis of 222 COVID patients to compare those who were admitted or readmitted after being cleared of the virus, with those who were hospitalized pre-clearance but were not re-admitted post-clearance. The researchers used nference state-of-the-artificial intelligence software for the augmented curation of comorbidities and complications, analyzing free-form text data including historical physician notes in the patients studied.
“nference and Mayo Clinic researchers applied nference AI-driven technology to unearth insights buried in clinical notes by turning unstructured data into computable data,” says Venky Soundararajan, PhD, co-founder and chief scientific officer of nference. “The results we obtained so rapidly using augmented curation and automation would have taken significantly longer than if done manually.”
Craftly.AI Launches AI-Powered Copywriting Platform
Craftly.AI is a web-based artificial intelligence writing platform that uses natural language processing and machine learning to analyze content research and write original articles that are plagiarism-free.
Craftly.AI recently launched a web-based AI-Powered Copywriter that leverages natural language processing and machine learning to research and write original content in seconds, not weeks.
Craftly is an AI-powered copywriter assistant that automates and transforms a large part of the writing process, so marketers can spend more time doing what they do best. On average, a customer will see more than 200 pieces of digital communication before converting. Artificial intelligence creates programs capable of crafting thousands of pieces of content within minutes.
Every piece of content that it generates is 100% original. Craftly works with a Machine Learning algorithm that runs on the breakthrough GPT-3 technology that can understand and emulate human communication style. This fully automatic content generation engine runs completely online, so there is no software to download. It can be used for webpage, social media posts, blog posts, ads, and more. Craftly was originally designed as a platform for social media and marketing teams to create their customer messaging tool kit.
Antares Pharma Uses Aktana Engagement Solution
Aktana announced the release of a dedicated configuration of its AI offering tailored to the needs of emerging and mid-sized biopharma companies. The new Aktana Contextual Intelligence offering provides commercial teams at any sized organization with the right insights and content at the right time to personalize the HCP relationship.
Leveraging a modular AI approach, commercial teams can easily configure a right size solution for quickly identifying the right targets, predicting the ideal timing and content for maximum HCP engagement, and prioritizing next best actions that users are most likely to adopt. Aktana works with more than half of the world’s top-20 pharmaceutical companies to incorporate data and insights across all sources, creating a personalized, omnichannel customer experience. (PV)